Investor Presentation First Nine Months of 2023
44
Investor presentation
First nine months of 2023
Novo Nordisk has 54% of the global GLP-1 market, while GLP-1
penetration of diabetes volume varies across regions
80%
60%
40%
20%
GLP-1 market growth and Novo Nordisk market share
Novo NordiskⓇ
GLP-1 share of total estimated diabetes prescriptions¹ is 6%
Million prescriptions¹
250
66%
200
62%
Global: 2%
54%
150
52%
100
50
0
0%
Aug
Aug
2018
2020
2023
-NN market share
NN share of growth
GLP-1
-Market growth
Source: IQVIA MAT value (spot rate), Aug 2023; Market values are based on the list prices
-NN growth
SGLT-2i
DPP-4i
Insulin
Global: 6%
2023
Trad. OAD
GLP-1 share of estimated diabetes prescriptions
1 The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-
year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk
assumptions
Source: IQVIA MAT volume (Spot rate), Aug 2023; Market values are based on the list pricesView entire presentation